Related Experiment Video
Updated: May 19, 2026
08:41
Dissection of Single Skeletal Muscle Fibers for Immunofluorescent and Morphometric Analyses of Whole-Mount Neuromuscular Junctions
Published on: August 14, 2021
Myasthenia and the neuromuscular junction
1Department of Clinical Medicine, University of Bergen, Bergen, Norway. nils.gilhus@helse-bergen.no
Current Opinion in Neurology
|August 16, 2012
Summary
Myasthenic syndromes, including myasthenia gravis, require further classification into subgroups. New therapeutic strategies are emerging, but more research is needed for effective, long-term patient management.
Area of Science:
- Neurology
- Immunology
- Genetics
Background:
- Myasthenic syndromes represent distinct neuromuscular junction disorders with known autoimmune or genetic causes.
- Understanding these dysfunctions offers insights into normal neuromuscular function and guides personalized therapeutic approaches.
Purpose of the Study:
- To review recent advancements in the classification and understanding of myasthenic syndromes.
- To highlight emerging therapeutic strategies and the need for further research in managing these conditions.
Main Methods:
- Review of current literature on myasthenic syndromes and myasthenia gravis.
- Analysis of newly identified patient subgroups and autoantibody profiles.
- Evaluation of existing and emerging treatment modalities.
Main Results:
- Myasthenia gravis and congenital myasthenic syndromes necessitate further subgroup classification.
- New subgroups include myasthenia gravis with low-affinity acetylcholine receptor (AChR) antibodies and anti-low-density lipoprotein receptor-related protein 4 antibodies.
- Myasthenia gravis with muscle-specific kinase (MuSK) antibodies is now as well-established as AChR-myasthenia gravis.
Conclusions:
- Myasthenic syndromes and myasthenia gravis are well-characterized, with generally good prognoses, except for paraneoplastic Lambert-Eaton myasthenic syndrome.
- Long-term symptomatic and immunomodulatory treatments are necessary, balancing efficacy against potential side effects.
- There is a need for more selective treatments, particularly for severe generalized disease, and high-quality clinical trials are essential.
Related Concept Videos
01:19The Neuromuscular Junction
The nervous system consists of complex motor neuron circuits, including upper motor neurons originating from the cerebral cortex and lower motor neurons starting in the spinal cord, coordinating both voluntary and involuntary movements. Among these, somatic motor neurons activate skeletal muscles and are classified into alpha, beta, and gamma types. Alpha neurons are vital for voluntary movement coordination, while gamma neurons adjust muscle spindle sensitivity, and the function of beta...
01:29Neuromuscular Junction And Blockade
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...